Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q2 2024 · 10-Q
Revenue$8.62M$8.62M+28.4% vs Q2 2023 Net Income-$96.12M-$96.12MN/M vs Q2 2023 EPS Diluted-$1.69-$1.69N/M vs Q2 2023 Operating Income-$105,817,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$72,747,000N/M Margins · derivedOperating margin-1228.3%+167.7 pt vs Q2 2023
Net margin-1115.7%+132.9 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 1, 2024 · 32 d after period end